• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics Inc (NQ: TRDA )

17.95 +0.18 (+1.01%)
Streaming Delayed Price Updated: 11:51 AM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Entrada Therapeutics Inc

< Previous 1 2 Next >
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Today 7:00 EST
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
October 09, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
September 24, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
September 06, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 13, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 24, 2024
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – 
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 24, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 16, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 07, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
August 01, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
Entrada Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
April 04, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
March 29, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
February 09, 2023
From Entrada Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap